Status:
COMPLETED
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Lead Sponsor:
Ural State Medical University
Collaborating Sponsors:
Ural Institute of Cardiology
De Haar Research Foundation
Conditions:
Cardiorenal Syndrome
Chronic Allograft Nephropathy
Eligibility:
MALE
40-75 years
Phase:
PHASE4
Brief Summary
We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management ...
Detailed Description
Paricalcitol and calcitriol are identically effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (...
Eligibility Criteria
Inclusion
- Age 40-75
- Male
- History of chronic kidney disease and cardiorenal syndrome
- Written informed consent
Exclusion
- Female
- Acute illness
- Life-threat competitive illness
- Mental disorders
- Endocrinologic diseases (including diabetes mellitus, hyperparathyroidism, and other thyroid disorders)
- Need for dialyses
- Hypercalcemia
- Concomitant use of hormone or cytokine medication
- Participation to any drug-investigation during the previous 60 days as checked with VIP check
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT01265615
Start Date
October 1 2009
End Date
September 1 2010
Last Update
June 9 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
De Haar Research Foundation
Rotterdam, South Holland, Netherlands, 3071PR
2
Ural Institute of Cardiology
Yekaterinburg, Russia, 620144